Serum osteoprotegerin is associated with vascular stiffness and the onset of new cardiovascular events in hemodialysis patients |
Lee, Jung Eun
(Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine)
Kim, Hyung Jong (Department of Internal Medicine, CHA Bundang Medical Center, CHA University) Moon, Sung Jin (Department of Internal Medicine, Myongji Hospital) Nam, Ji Sun (Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine) Kim, Jwa-Kyung (Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine) Kim, Seung Kyu (Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine) Yun, Gi Young (Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine) Ha, Sung Kyu (Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine) Park, Hyeong Cheon (Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine) |
1 | Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000;15:1014-1021. DOI ScienceOn |
2 | Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calficications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001;38:938-942. DOI ScienceOn |
3 | Asmar R, Benetos A, Topouchian J, et al. Assesment of arterial distensibility by automatic pulse wave velocity measurement: validation and clinical application studies. Hypertension 1995;26:485-490. DOI ScienceOn |
4 | Lacey DL, Dunstan CR, Kelley M, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-319. DOI ScienceOn |
5 | Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93:165-176. DOI ScienceOn |
6 | Westenfeld R, Jahnen-Dechent W, Ketteler M. Vascular calcification and fetuin-A deficiency in chronic kidney disease. Trends Cardiovasc Med 2007;7:124-128. |
7 | Nishiura R, Fujimoto S, Sato Y, et al. Elevated osteoprotegerin levels predict cardiovascualr events in new hemodialysis patients. Am J Nephrol 2009;9:257-263. |
8 | Sigrist MK, Levin A, Er L, McIntyre CW. Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification. Nephrol Dial Transplant 2009;24:3157-3162. DOI ScienceOn |
9 | Nakashima A, Carrero JJ, Qureshi AR, et al. Plasma osteoprotegerin, arterial stiffness, and mortality in normoalbuminemic Japanese hemodialysis patients. Osteoporosis Int 2011;22:1695-1701. DOI ScienceOn |
10 | Speer G, Fekete BC, El Hadj Othmane T, et al. Serum osteoprotegerin level, carotid-femoral pulse wave velocity and cardiovascular survival in haemodialysis patients. Nephrol Dial Transplant 2008;23:3256-3262. DOI ScienceOn |
11 | Hermans MM, Brandenburg V, Ketteler M, et al. Study on the relationship of serum fetuin-A concentration with aortic stiffness in patients on dialysis. Nephrol Dial Transplant 2006;21:1293-1299. DOI ScienceOn |
12 | Ix JH, Shlipak MG, Sarnak MJ, et al. Fetuin-A is not associated with mortality in chronic kidney disease. Kidney Int 2007;72:1394-1399. DOI ScienceOn |
13 | Ketteler M, Bongartz P, Westenfeld R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a crosssectional study. Lancet 2003;361:827-833. DOI ScienceOn |
14 | Swedberg K, Cleland J, Dargie H, et al. Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology: guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur Heart J 2005;26:1115-1140. DOI ScienceOn |
15 | O'Rourke MF, Staessen JA, Vlachopoulos C, Duprez D, Plante GE. Clinical application of arterial stiffness: definitions and reference values. Am J Hypertens 2002;15:426-444. DOI ScienceOn |
16 | Park S, Kim JB, Shim CY, et al. The influence of serum aldosterone and the aldosterone-renin ratio on pulse wave velocity in hypertensive patients. J Hypertens 2007;25:1279-1283. DOI ScienceOn |
17 | London GM, Guerin AP, Verbeke FH, et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007;18:613-620. DOI ScienceOn |
18 | Kuzniar J, Porazko T, Klinger M. Relationship between fetuin-A concentration, elevated levels of inflammatory markers, and arterial wall stiffness in end stage kidney disease. J Ren Nutr 2008;18:83-86. DOI ScienceOn |
19 | Nitta K, Akiba T, Uchida K, et al. The progression of vascular calcification and serum osteoprogerin levels in patients on long-term hemodialysis. Am J Kidney Dis 2003;42:303-309. DOI ScienceOn |
20 | Barreto DV, Barreto FC, Carvalho AB, et al. Coronary calcification in hemodialysis patients: the contribution of traditional and uremia-related risk factors. Kidney Int 2005;67:1576-1582. DOI ScienceOn |
21 | Lebreton JP, Joisel F, Raoult JP, Lannuzel B, Rogez JP, Humbert G. Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acutephase reactant. J Clin Invest 1979;64:1118-1129. DOI |
22 | Stenvinkel P, Wang K, Qureshi AR, et al. Low fetuin-A levels are associated with cardiovascular death: impact of variations in the gene encoding fetuin. Kindey Int 2005;67:2383-2392. DOI ScienceOn |
23 | Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997;386:78-81. DOI ScienceOn |
24 | Schinke T, Amendt C, Trindl A, Poschke O, Muller-Esterl W, Jahnen-Dechent W. The serum protein alpha 2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells: a possible role in mineralization and calcium homeostasis. J Biol Chem 1996;271:20789-20796. DOI ScienceOn |
25 | Metry G, Stenvinkel P, Qureshi AR, et al. Low serum fetuin-A concentration predicts poor outcome only in the presence of inflammation in prevalent haemodialysis patients. Eur J Clin Invest 2008;38:804-811. DOI ScienceOn |
26 | Raggi P, Bellasi A, Ferramosca E, Islam T, Muntner P, Block GA. Association of pulse wave velocity with vascular and valvular calcification in hemodialysis patients. Kidney Int 2007;71:802-807. DOI ScienceOn |
27 | Honda H, Qureshi AR, Heimburger O, et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 2006;47:139-148. DOI ScienceOn |
28 | Chen HY, Chiu YL, Hsu SP, et al. Association of serum fetuin A with truncal obesity and dyslipidemia in non-diabetic hemodialysis patients. Eur J Endocrinol 2009;160:777-783. DOI ScienceOn |
29 | Scialla JJ, Leonard MB, Townsend RR, et al. Correlates of osteoprotegerin and association with aortic pulse wave velocity in patients with chronic kidney disease. Clin J Am Soc Nephrol 2011;6:2612-2619. DOI |
30 | Haydar AA, Covic A, Colhoun H, Rubens M, Goldsmith DJ. Coronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients. Kidney Int 2004;65:1790-1794. DOI ScienceOn |
31 | Hjelmesaeth J, Ueland T, Flyvbjerg A, et al. Early posttransplant serum osteoprotegerin levels predict long-term (8-year) patient survival and cardiovascular death in renal transplant patients. J Am Soc Nephrol 2006;17:1746-1754. DOI ScienceOn |
32 | Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004;109:2175-2180. DOI ScienceOn |
33 | Morena M, Terrier N, Jaussent I, et al. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol 2006;17:262-270. DOI ScienceOn |
![]() |